Latest Ratios: P/E Ratio 22.7x · EV/EBITDA 9.6x · ROE 4.7%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $1.3B | $2.1B | $3.5B | $2.7B | $4.6B | $3.3B | $3.3B | $1.9B | $1.4B | $1.2B |
| Enterprise Value | $1.8B | $2.1B | $3.0B | $4.4B | $3.7B | $5.2B | $4.0B | $4.1B | $2.3B | $1.9B | $1.7B |
| P/E Ratio → | 22.68 | 26.89 | 16.07 | 53.68 | — | 73.07 | 350.00 | 115.29 | 45.53 | 25.87 | 84.94 |
| P/S Ratio | 0.77 | 0.92 | 1.63 | 2.78 | 2.55 | 4.52 | 3.83 | 3.45 | 2.16 | 1.80 | 1.62 |
| P/B Ratio | 1.03 | 1.22 | 2.21 | 4.14 | 3.57 | 5.81 | 4.65 | 4.64 | 2.80 | 2.27 | 2.13 |
| P/FCF | 7.00 | 8.38 | 13.84 | 32.50 | 229.94 | 47.13 | 64.05 | 43.94 | 31.87 | 27.23 | 52.63 |
| P/OCF | 6.19 | 7.41 | 12.75 | 27.56 | 79.81 | 40.86 | 51.14 | 34.67 | 24.83 | 21.90 | 32.32 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.50 | 2.30 | 3.55 | 3.53 | 5.18 | 4.69 | 4.26 | 2.67 | 2.37 | 2.22 |
| EV / EBITDA | 9.56 | 10.64 | 11.06 | 22.97 | 30.79 | 28.99 | 34.13 | 26.85 | 17.24 | 17.91 | 18.24 |
| EV / EBIT | 13.11 | 14.59 | 15.03 | 36.66 | — | 48.17 | 88.69 | 55.00 | 32.17 | 40.26 | 48.83 |
| EV / FCF | — | 13.64 | 19.56 | 41.59 | 318.53 | 53.98 | 78.60 | 54.16 | 39.42 | 35.84 | 72.27 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.8% | 52.8% | 56.1% | 54.3% | 54.6% | 56.2% | 53.4% | 54.9% | 54.6% | 54.1% | 53.5% |
| Operating Margin | 10.3% | 10.3% | 15.3% | 9.7% | 6.7% | 10.9% | 5.3% | 8.3% | 8.3% | 5.9% | 4.9% |
| Net Profit Margin | 3.4% | 3.4% | 10.1% | 5.2% | -7.7% | 6.2% | 1.1% | 3.0% | 4.8% | 7.0% | 1.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.7% | 4.7% | 14.7% | 8.2% | -10.5% | 8.4% | 1.3% | 4.2% | 6.3% | 9.2% | 2.5% |
| ROA | 2.0% | 2.0% | 5.7% | 2.8% | -4.0% | 3.6% | 0.5% | 1.8% | 3.0% | 4.1% | 1.2% |
| ROIC | 5.8% | 5.8% | 8.2% | 5.1% | 3.3% | 5.7% | 2.4% | 4.6% | 4.9% | 3.3% | 3.1% |
| ROCE | 7.0% | 7.0% | 10.0% | 6.0% | 3.9% | 7.0% | 2.9% | 5.7% | 5.9% | 3.9% | 3.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.81 | 0.81 | 0.94 | 1.19 | 1.41 | 0.87 | 1.10 | 1.12 | 0.69 | 0.77 | 0.84 |
| Debt / EBITDA | 4.32 | 4.32 | 3.33 | 5.15 | 8.80 | 3.79 | 6.54 | 5.24 | 3.43 | 4.61 | 5.25 |
| Net Debt / Equity | — | 0.77 | 0.92 | 1.16 | 1.38 | 0.85 | 1.06 | 1.08 | 0.66 | 0.72 | 0.79 |
| Net Debt / EBITDA | 4.10 | 4.10 | 3.24 | 5.02 | 8.56 | 3.68 | 6.31 | 5.07 | 3.30 | 4.30 | 4.96 |
| Debt / FCF | — | 5.26 | 5.73 | 9.10 | 88.59 | 6.85 | 14.54 | 10.22 | 7.55 | 8.61 | 19.64 |
| Interest Coverage | 4.54 | 4.54 | 5.37 | 3.03 | -1.45 | 3.06 | 1.04 | 1.73 | 3.45 | 2.58 | 2.26 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.14 | 2.14 | 2.30 | 1.98 | 1.96 | 2.34 | 2.19 | 2.11 | 2.33 | 2.38 | 2.90 |
| Quick Ratio | 1.01 | 1.01 | 1.05 | 0.96 | 0.84 | 1.16 | 1.17 | 1.24 | 1.37 | 1.44 | 1.71 |
| Cash Ratio | 0.13 | 0.13 | 0.09 | 0.08 | 0.10 | 0.11 | 0.14 | 0.14 | 0.11 | 0.22 | 0.24 |
| Asset Turnover | — | 0.59 | 0.57 | 0.54 | 0.46 | 0.57 | 0.49 | 0.54 | 0.63 | 0.59 | 0.57 |
| Inventory Turnover | 1.83 | 1.83 | 1.66 | 1.79 | 1.43 | 1.91 | 2.06 | 2.61 | 2.53 | 2.58 | 2.61 |
| Days Sales Outstanding | — | 65.81 | 66.39 | 71.04 | 66.80 | 66.41 | 74.97 | 72.27 | 77.09 | 76.56 | 70.87 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.3% | 2.0% | 1.2% | 0.7% | 0.9% | 0.5% | 0.7% | 0.7% | 1.2% | 1.6% | 1.8% |
| Payout Ratio | 52.6% | 52.6% | 18.6% | 38.0% | — | 37.2% | 239.8% | 79.0% | 54.9% | 40.2% | 151.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.4% | 3.7% | 6.2% | 1.9% | — | 1.4% | 0.3% | 0.9% | 2.2% | 3.9% | 1.2% |
| FCF Yield | 14.3% | 11.9% | 7.2% | 3.1% | 0.4% | 2.1% | 1.6% | 2.3% | 3.1% | 3.7% | 1.9% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 2.7% | 0.0% | 0.0% | 0.9% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 2.3% | 2.0% | 1.2% | 0.7% | 3.6% | 0.5% | 0.7% | 1.6% | 1.2% | 1.6% | 1.8% |
| Shares Outstanding | — | $31M | $31M | $32M | $30M | $32M | $29M | $29M | $29M | $28M | $28M |
High leverage and goodwill
According to current market data, CNMD trades at a P/E of 23.81, yet the forward P/E of 8.24 suggests that investors are pricing in significant earnings recovery, a sentiment further supported by a PEG ratio of 0.65 which implies the market may be undervaluing potential growth catalysts.
The divergence between trailing and forward multiples indicates that the market is heavily discounting near-term volatility in favor of anticipated margin expansion. Investors should monitor whether this valuation gap is a result of overly optimistic analyst forecasts or a genuine mispricing of the company's recurring revenue potential in the surgical disposables market.
Based on reported financial statements, ROIC has remained suppressed, fluctuating between 0.5% and 2.7% over the last ten quarters, which suggests that the company is struggling to generate meaningful returns on the capital deployed for its aggressive acquisition strategy within the medical device sector.
The consistently low ROIC relative to industry peers indicates that the integration of recent acquisitions has yet to yield the expected synergies. This trend warrants investigation into whether the company's capital allocation is effectively compounding value or merely expanding the asset base without improving underlying operational efficiency.
As reported in recent quarterly filings, the cash conversion cycle has remained elevated, peaking at 214 days in 2025Q1, which highlights significant inefficiencies in managing inventory and receivables compared to more agile competitors in the medical device space who maintain tighter control over their operational working capital.
The extended duration of the cash conversion cycle suggests that capital is being trapped in inventory, likely due to the diverse SKU requirements of the orthopedic portfolio. This inefficiency limits the company's ability to self-fund growth and necessitates a closer look at whether supply chain management can be optimized to improve liquidity.
According to quarterly balance sheet data, the company's debt-to-EBITDA ratio has shown extreme volatility, reaching as high as 36.54 in 2025Q1, which indicates that the current leverage profile is highly sensitive to operational earnings fluctuations and poses a significant risk to the company's long-term financial stability.
The high interest coverage volatility suggests that the company's debt service capacity is precarious, leaving little room for error during periods of revenue contraction. Investors should be wary of the potential for covenant pressure if operating margins do not stabilize, as the current debt load appears to be a structural drag on performance.
The P/E ratio is frequently misapplied to this business model because it fails to account for the heavy non-cash amortization charges resulting from past acquisitions, which artificially depress reported net income and obscure the company's actual cash-generating capacity in the high-margin surgical disposables segment.
Analysts should instead prioritize EV/EBITDA or P/FCF to better capture the underlying operational performance, as these metrics strip away the accounting noise associated with intangible asset write-downs. Relying solely on P/E risks misinterpreting the company's true valuation by focusing on accounting earnings rather than the cash flow reality of the business.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CNMD stock.
CONMED Corporation's current P/E ratio is 22.7x. The historical average is 32.8x. This places it at the 48th percentile of its historical range.
CONMED Corporation's current EV/EBITDA is 9.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.8x.
CONMED Corporation's return on equity (ROE) is 4.7%. The historical average is 6.0%.
Based on historical data, CONMED Corporation is trading at a P/E of 22.7x. This is at the 48th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
CONMED Corporation's current dividend yield is 2.32% with a payout ratio of 52.6%.
CONMED Corporation has 52.8% gross margin and 10.3% operating margin. Operating margin between 10-20% is typical for established companies.
CONMED Corporation's Debt/EBITDA ratio is 4.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.